2. Metabolic Enzyme/Protease
  3. Endogenous Metabolite
  4. nNIF peptide

nNIF peptide is an endogenous polypeptide detectable in human umbilical cords and neonatal blood. nNIF peptide specifically inhibits neutrophil extracellular trap (NETs) formation by neutrophils without interfering with other key immune functions of neutrophils. nNIF peptide can be used in studies related to COVID-19 acute respiratory distress syndrome, polymicrobial sepsis, and neonatal infectious peritonitis.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

nNIF peptide

nNIF peptide Chemical Structure

CAS No. : 1644397-65-8

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of nNIF peptide:

nNIF peptide Related Antibodies

Top Publications Citing Use of Products

View All Endogenous Metabolite Isoform Specific Products:

View All Isoforms
Human Endogenous Metabolite Microbial Metabolite

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

nNIF peptide is an endogenous polypeptide detectable in human umbilical cords and neonatal blood. nNIF peptide specifically inhibits neutrophil extracellular trap (NETs) formation by neutrophils without interfering with other key immune functions of neutrophils. nNIF peptide can be used in studies related to COVID-19 acute respiratory distress syndrome, polymicrobial sepsis, and neonatal infectious peritonitis[1][2][3].

In Vitro

nNIF peptide (1 nM; 1-2 h) potently blocks neutrophil extracellular trap (NET) formation in primary neutrophils (PMNs) isolated from healthy adult donors, which is induced by plasma from COVID-19 patients[1].
The nNIF peptide (1 nM; 1.5 h) does not alter reactive oxygen species production in neutrophils isolated from the spleens of outbred Swiss Webster mice aged 7 to 10 days and stimulated with PMA (HY-18739)[3].
Treatment with nNIF peptide (1 nM; 3 h) does not alter the phagocytosis of fluorescently labeled E. coli bioparticles by neutrophils isolated from the spleens of outbred Swiss Webster mice aged 7-10 days[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

nNIF peptide Related Antibodies
In Vivo

nNIF peptide (0.1-1 mg/kg; i.v.; administered twice) dose-dependently improves survival in a sepsis model of Swiss Webster mice. The 6-day survival rates reach 70% and 73% in the 0.5 mg/kg and 1 mg/kg dose groups, respectively. Meanwhile, it reduces NET formation, alleviates disease severity, and decreases peritoneal TNF-α levels[2].
nNIF peptide (1 mg/kg; i.v.; administered twice), as an adjuvant therapy to suboptimal Meropenem (HY-13678), increases the 6-day survival rate to 90% in a sepsis model of Swiss Webster mice, while improving disease severity and normalizing late-stage bacterial CFU levels[2].
nNIF peptide (10 mg/kg; i.p.; two administrations) significantly increases the survival rate of neonatal mice with cecal slurry-induced infectious peritonitis to 47%, while reducing peritoneal neutrophil extracellular trap (NET) formation, proinflammatory cytokine levels and circulating platelet-neutrophil aggregates, and increasing peritoneal neutrophil counts and bacterial loads[3].
nNIF peptide (10 mg/kg; i.p.; 2 administrations), as an adjuvant therapy, significantly increases the survival rate of neonatal mice with cecal homogenate-induced infectious peritonitis receiving sub-dose Meropenem to 83-100%[3].
nNIF peptide (10 mg/kg; i.p.; 2 administrations) significantly increases the survival rate of neonatal mice with cecal slurry-induced infectious peritonitis to 18%[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Swiss Webster (male, 8 weeks old, 25-27 grams, CLP-induced polymicrobial sepsis)[2]
Dosage: 0.1 mg/kg; 0.5 mg/kg; 1 mg/kg
Administration: i.v.; 2 doses at 4 and 10 hours after CLP
Result: Achieved 30% 6-day survival rate and showed minimal improvement in illness severity scores compared to vehicle control at 0.1 mg/kg.
Achieved 70% 6-day survival rate, improved illness severity scores at 48 hours compared to vehicle control, decreased peritoneal fluid and plasma MPO-DNA complexes (NET formation) compared to vehicle/scrambled peptide control, increased peritoneal fluid and whole blood aerobic bacterial CFUs compared to vehicle/scrambled peptide control, and decreased peritoneal fluid TNF-α levels compared to vehicle/scrambled peptide/meropenem groups at 0.5 mg/kg.
Achieved 73% 6-day survival rate, improved illness severity scores at 24 and 48 hours compared to vehicle control, decreased peritoneal fluid and plasma MPO-DNA complexes (NET formation) compared to vehicle/scrambled peptide/meropenem groups, significantly decreased peritoneal fluid neutrophil CD11b expression compared to scrambled peptide control, increased peritoneal fluid and whole blood aerobic bacterial CFUs compared to vehicle/scrambled peptide control, and decreased peritoneal fluid TNF-α levels compared to vehicle/scrambled peptide/meropenem groups at 1 mg/kg.
Animal Model: Swiss Webster (male, 8 weeks old, 25-27 grams, CLP-induced polymicrobial sepsis with suboptimal antibiotic treatment)[2]
Dosage: 1 mg/kg (nNIF); 8 mg/kg (meropenem)
Administration: i.v. (nNIF; 2 doses at 4 and 10 hours after CLP); i.p. (meropenem; 2 initial doses at 4 and 10 hours after CLP then daily for 6 days)
Result: Achieved 90% 6-day survival rate (compared to 40% with suboptimal meropenem alone and 30% with suboptimal meropenem + scrambled peptide).
Improved illness severity scores at 24 and 48 hours compared to vehicle control.
Decreased peritoneal fluid bacterial CFUs at 96 hours compared to nNIF alone or meropenem alone groups.
Showed whole blood bacterial CFUs at 96 hours equivalent to meropenem alone levels (after being elevated at 24 hours compared to other groups).
Animal Model: outbred Swiss Webster mice (7-10-day-old, cecal slurry-induced infectious peritonitis)[3]
Dosage: 10 mg/kg
Administration: i.p.; 2 doses (1 h pre-cecal slurry injection and 4 h post-cecal slurry injection)
Result: Significantly decreased peritoneal MPO-DNA complex levels at 24 hours post-cecal slurry injection.
Significantly reduced peritoneal fluid levels of TNF-α, CXCL1, and IL-6 at 24 hours post-cecal slurry injection.
Significantly decreased circulating platelet-neutrophil aggregates at 24 hours post-cecal slurry injection.
Significantly increased peritoneal neutrophil counts at 24 hours post-cecal slurry injection compared to nNIF-SCR controls.
Significantly increased aerobic bacterial colony forming units in peritoneal fluid compared to nNIF-SCR controls.
Resulted in a 47% survival rate over 6 days, which was significantly higher than the 9% survival rate of nNIF-SCR treated mice.
Combination treatment with 10 mg/kg nNIF and 5 mg/kg meropenem significantly improved survival to 83% compared to 29% survival with 5 mg/kg meropenem alone.
Combination treatment with 10 mg/kg nNIF and 10 mg/kg meropenem significantly improved survival to 100% compared to 40% survival with 10 mg/kg meropenem alone.
Animal Model: outbred Swiss Webster mice (7-10-day-old, cecal slurry-induced infectious peritonitis)[3]
Dosage: 10 mg/kg
Administration: i.p.; 2 doses (2 h post-cecal slurry injection and 6 h post-cecal slurry injection)
Result: Delayed nNIF treatment alone resulted in an 18% survival rate, which was significantly higher than the survival rate of nNIF-SCR treated mice.
Combination treatment with 10 mg/kg nNIF and 10 mg/kg meropenem resulted in 100% survival, which was significantly higher than the 48% survival rate with 10 mg/kg meropenem alone.
Molecular Weight

3384.02

Formula

C158H248N38O40S2
CAS No.
Sequence

Lys-Phe-Asn-Lys-Pro-Phe-Val-Phe-Leu-Met-Ile-Glu-Gln-Asn-Thr-Lys-Ser-Pro-Leu-Phe-Met-Gly-Lys-Val-Val-Asn-Pro-Thr-Gln
Sequence Shortening

KFNKPFVFLMIEQNTKSPLFMGKVVNPTQ
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

nNIF peptide Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

nNIF peptide1644397-65-8Endogenous Metabolitepolymorphonuclear leukocytespro-inflammatory cytokineCD11bE. coliCOVID-19 acute respiratory distress syndromemurine polymicrobial sepsisplatelet-neutrophil aggregatesneutrophil extracellular trapSwiss Webster miceneonatal infectious peritonitisInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
nNIF peptide
Cat. No.:
HY-P11791
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.